RxDoctor Payments Data

James Gosset, MD

Cardiovascular Disease · Milwaukee, WINPI 1144335407

Payments from drug & device makers

$593in general payments, 2019–2025

Across 12 payments — averaging $49.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$259
  • Pfizer$86
  • W. L. Gore & Associates, Inc.$79
  • Tactile Systems Technology Inc$57
  • Novartis$43
  • Alnylam Pharmaceuticals Inc.$29
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$593100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$593 in reported general payments places this provider in the 40th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$52,097
Medicare patients
281
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$249,070
XareltoRivaroxaban40$52,455
Pentoxifylline163$9,240
Cilostazol144$3,773
Atorvastatin Calcium143$1,238
Warfarin Sodium34$564
ClopidogrelClopidogrel Bisulfate26$226
Triamcinolone Acetonide26$202
Rosuvastatin Calcium30$197
Amlodipine Besylate11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$249,070220 claims
Johnson & JohnsonXarelto$259$52,45540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →